Q2 Earnings Estimate for Pharvaris Issued By Leerink Partnrs

Pharvaris (NASDAQ:PHVS) – Stock analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for Pharvaris in a research report issued to clients and investors on Tuesday, May 13th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.87) for the quarter, up from their prior forecast of ($0.91). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris’ Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($3.58) EPS and FY2026 earnings at ($3.26) EPS.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09).

PHVS has been the subject of a number of other reports. JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st. Cantor Fitzgerald lowered their price target on Pharvaris from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday.

Pharvaris Stock Performance

PHVS opened at $15.91 on Friday. The company has a fifty day moving average price of $15.37 and a two-hundred day moving average price of $17.73. The firm has a market capitalization of $831.93 million, a PE ratio of -5.68 and a beta of -2.85. Pharvaris has a 52 week low of $11.51 and a 52 week high of $25.50.

Institutional Trading of Pharvaris

A number of large investors have recently made changes to their positions in PHVS. Soleus Capital Management L.P. lifted its holdings in Pharvaris by 36.2% during the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock worth $15,617,000 after acquiring an additional 216,483 shares in the last quarter. FMR LLC lifted its holdings in shares of Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock valued at $103,429,000 after purchasing an additional 189,714 shares in the last quarter. Octagon Capital Advisors LP grew its position in shares of Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after purchasing an additional 157,530 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after purchasing an additional 118,408 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Pharvaris by 483.9% during the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company’s stock worth $1,762,000 after buying an additional 76,188 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.